MedTrace Logo

A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers

NCT05236998 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2022-10-26

No results posted yet for this study

Summary

This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of SID1903 and SID1903-R1/SID1903-R2 in healthy adult volunteers.

Conditions

  • Healthy Subjects

Interventions

DRUG

SID1903 (FDC)

Single oral administration of SID1903 (FDC) after an overnight fast

DRUG

Dapagliflozin and Sitagliptin

Single oral administration of Dapagliflozin and Sitagliptin after an overnight fast

Sponsors & Collaborators

  • SK Chemicals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-03
Primary Completion
2021-12-21
Completion
2021-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05236998 on ClinicalTrials.gov